Export 55 results:
Author Title Type [ Year
Filters: First Letter Of Title is F [Clear All Filters]
“First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E.”, Antimicrob Agents Chemother, vol. 66, no. 4, p. e0173221, 2022.
, “Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9.”, Am J Ophthalmol, vol. 228, pp. 27-34, 2021.
, “Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy.”, Neurology, vol. 94, no. 14, pp. e1502-e1511, 2020.
, “Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.”, NPJ Vaccines, vol. 5, no. 1, p. 6, 2020.
, “Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials.”, Front Med (Lausanne), vol. 6, p. 122, 2019.
, “Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.”, JAMA Oncol, 2019.
, “Finding Common Ground and Advancing Engagement in Citizen Science.”, Narrat Inq Bioeth, vol. 9, no. 1, pp. 41-45, 2019.
, “Frailty in medically complex individuals with chronic HIV.”, AIDS, vol. 33, no. 10, pp. 1603-1611, 2019.
, , “Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601.”, Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
, “Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.”, Addiction, vol. 112, no. 6, pp. 1036-1044, 2017.
, , “Fidelity Monitoring Model for an MI-Based Brief Intervention”, in 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD), Phoenix, AZ, 2015.
, “First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)”, J Infect Dis, vol. 210, pp. 1052-1061, 2014.
, “First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).”, J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.
, “Factors Influencing Adherence Behavior for Daily and Intermittent Regimens of Pre-Exposure Prophylaxis (PrEP) Among Men Who Have Sex With Men (MSM) in Kenya”, in Adherence 2013, Miami, FL, 2013.
, “Factors Predicting Health Related Quality of Life in Pediatric Liver Transplant Recipients in the Functional Outcomes Group”, Pediatr Transplant, vol. 17, pp. 605-611, 2013.
, “Factors predicting health-related quality of life in pediatric liver transplant recipients in the functional outcomes group.”, Pediatr Transplant, vol. 17, no. 7, pp. 605-11, 2013.
, “Fetal Antiepileptic Drug Exposure: Adaptive and Emotional/Behavioral Functioning at Age 6 Years”, Epilepsy Behav, vol. 29, pp. 308-315, 2013.
, “Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years.”, Epilepsy Behav, vol. 29, no. 2, pp. 308-15, 2013.
, “Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.”, Lancet Neurol, vol. 12, no. 3, pp. 244-52, 2013.
, “Fetal Antiepileptic Drug Exposure and Cognitive Outcomes at Age 6 Years (NEAD Study): A Prospective Observational Study”, Lancet Neurol, vol. 12, pp. 244-252, 2013.
, “Finding Your First Industry Job”, in International Biometric Society - Eastern North American Region (ENAR), Orlando, FL, 2013.
, “First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)”, J Infect Dis, vol. 207, pp. 240-247, 2013.
, “First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
,